Get the Stockscreener App
3.75
1.63%
0.06
After Hours:
3.66
-0.09
-2.40%
Amylyx Pharmaceuticals Inc stock is traded at $3.75, with a volume of 813.06K.
It is up +1.63% in the last 24 hours and down -4.34% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
See More
Previous Close:
$3.69
Open:
$3.7
24h Volume:
813.06K
Relative Volume:
0.78
Market Cap:
$321.34M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
5.3571
EPS:
0.7
Net Cash Flow:
$10.68M
1W Performance:
+6.84%
1M Performance:
-4.34%
6M Performance:
+90.36%
1Y Performance:
-75.90%
1-Day Range:
$3.665
$3.83
1-Week Range:
$3.355
$3.8988
52-Week Range:
$1.575
$19.95
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
3.75 | 321.34M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells 3,678 Shares of Stock - MarketBeat
Amylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in shares - MSN
Amylyx Pharmaceuticals Executives Cash In on Stock Sales - TipRanks
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation - Markets Insider
Research Analysts Set Expectations for AMLX FY2025 Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - Markets Insider
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Rises By 23.6% - MarketBeat
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - Markets Insider
AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
2025-02-02 | Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:AMLX | Press Release - Stockhouse Publishing
JPMorgan Chase & Co. Purchases 83,048 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Leerink Partnrs Brokers Increase Earnings Estimates for AMLX - Defense World
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - Markets Insider
2025-01-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation | NDAQ:AMLX | Press Release - Stockhouse Publishing
FDA lifts clinical hold on Amylyx ALS drug study - MSN
FDA clears Amylyx to resume ALS drug trial in North America - MSN
Fierce Biotech Names Amylyx Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2020 - Marketscreener.com
Clinical hold lifted from Phase 1 trial of ALS therapy AMX0114 - ALS News Today
FDA lifts clinical hold on Amylyx’s Phase I ALS trial - MSN
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets - BioSpace
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Hennion & Walsh Asset Management Inc. - Defense World
Amylyx Says FDA Lifts Clinical Hold on ALS-Drug Trial - MarketWatch
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis - Business Wire
Barclays PLC Buys 40,319 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - AccessWire
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - AccessWire
Amylyx Pharmaceuticals Prices of Public Offering of Common Stock - citybiz
Amylyx stock dips after pricing $60M stock offering - MSN
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Announces Common Stock Offering to Fuel Commercialization Plans - StockTitan
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
Amylyx Pharmaceuticals co-CEO Justin Klee sells $30,201 in stock By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - AccessWire
Justin B. Klee Sells 7,471 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock - MarketBeat
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells shares worth $30,232 By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells shares worth $30,232 - Investing.com
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
ALS drugs from Denali, Calico come up short, marking more failures for Healey trial - BioPharma Dive
Denali Suffers Another ALS Fail With Phase II/III Flop - BioSpace
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):